// App-Quantinova.ai

2556.0 : Ibrutinib-based combination therapy exhibited therapeutic benefit in newly diagnosed primary central nervous system lymphoma.

Researchers

Presenter

  • Feili Chen

Principal Investigators

  • Diwen Pang

  • Hanguo Guo

  • Qiuxiang Ou

  • Xue Wu

  • Xinmiao Jiang

  • Xiaojuan Wei

  • Sichu Liu

  • Ling Huang

  • Zhanli Liang

  • Wenyu Li

Medical Centers

  • Provincial People's Hospital, Guangzhou, China

  • Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada

Locations

  • China

  • Canada

Companies

  • Geneseeq Technology

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved